db_pavan's profile picture. Precision Medicine Enthusiast. Cricket Lover and Chelsea FC Fanatic.

Pavan Anne

@db_pavan

Precision Medicine Enthusiast. Cricket Lover and Chelsea FC Fanatic.

You might like

ZS's innovative digital solution for rare disease diagnosis has been recognized as a finalist in the Fierce Life Sciences Innovation Awards. #DigitalHealth #FierceInnovation #RareDiseaseCare bit.ly/47uxgHm

db_pavan's tweet image. ZS's innovative digital solution for rare disease diagnosis has been recognized as a finalist in the Fierce Life Sciences Innovation Awards. #DigitalHealth #FierceInnovation #RareDiseaseCare bit.ly/47uxgHm

AI, data and diagnostics are transforming precision medicine. Explore how next-generation Rx-Dx partnerships are evolving from single-test collaborations to shared ecosystems built on trust, flexibility and innovation. bit.ly/48JHCFD

db_pavan's tweet image. AI, data and diagnostics are transforming precision medicine. Explore how next-generation Rx-Dx partnerships are evolving from single-test collaborations to shared ecosystems built on trust, flexibility and innovation. bit.ly/48JHCFD

ZS named a Leader in IDC MarketScape analyst report for HCP engagement

db_pavan's tweet image. ZS named a Leader in IDC MarketScape analyst report for HCP engagement

Emerging biopharma first launches held steady in the U.S. in 2024, while the EU saw just one. Our analysis explores the commercialization paths, launch performance and future trajectories of novel first launchers. We also examine what happens postlaunch—how many scale, stall...

db_pavan's tweet image. Emerging biopharma first launches held steady in the U.S. in 2024, while the EU saw just one. Our analysis explores the commercialization paths, launch performance and future trajectories of novel first launchers. We also examine what happens postlaunch—how many scale, stall...

🗺️ Map out your onsite adventure at Dreamforce 2025 and learn how ZS is redefining what CRMs can do. See how to leverage tech and AI to climb faster and scale smarter to create better customer experiences. bit.ly/4gxR6Wk #DF25 #SafesforcePartner #CRM

db_pavan's tweet image. 🗺️ Map out your onsite adventure at Dreamforce 2025 and learn how ZS is redefining what CRMs can do. See how to leverage tech and AI to climb faster and scale smarter to create better customer experiences. bit.ly/4gxR6Wk #DF25 #SafesforcePartner #CRM

Join ZS at the 15th World CB & CDx Summit

db_pavan's tweet image. Join ZS at the 15th World CB & CDx Summit

A smarter CRM strategy for CDIOs and tech leaders

db_pavan's tweet image. A smarter CRM strategy for CDIOs and tech leaders

Salesforce unveils life sciences partner network to accelerate digital labor and data programs

db_pavan's tweet image. Salesforce unveils life sciences partner network to accelerate digital labor and data programs

How CRM can help pharma break barriers and transform customer engagement bit.ly/43v1WYa


Balancing personal and nonpersonal resources isn’t easy for medical affairs organizations—but our action plan can help. Download the white paper: bit.ly/3Fg4yzM #Pharma #MedicalAffairs

db_pavan's tweet image. Balancing personal and nonpersonal resources isn’t easy for medical affairs organizations—but our action plan can help. Download the white paper: bit.ly/3Fg4yzM #Pharma #MedicalAffairs

ZS Discovery’s Claus Lundegaard and Milena Vujovic explore how epitope-focused cancer vaccines and in-silico methods could have the power to transform cancer immunology. Read the full story: bit.ly/4kSwXfp #ZSDiscovery #Oncology #Vaccines

db_pavan's tweet image. ZS Discovery’s Claus Lundegaard and Milena Vujovic explore how epitope-focused cancer vaccines and in-silico methods could have the power to transform cancer immunology. Read the full story: bit.ly/4kSwXfp #ZSDiscovery #Oncology #Vaccines

ZS and NCODA are proud to share that the 2024 NCODA Oncology Institute - Delivering Equitable Care through Partnership with Industry and the Oncology Community has received a PM360 PharmaChoice Silver Award in the Multicultural category. This award, voted on by industry peers,...

db_pavan's tweet image. ZS and NCODA are proud to share that the 2024 NCODA Oncology Institute - Delivering Equitable Care through Partnership with Industry and the Oncology Community has received a PM360 PharmaChoice Silver Award in the Multicultural category. This award, voted on by industry peers,...

2025 LSX World Congress panel discussion

db_pavan's tweet image. 2025 LSX World Congress panel discussion

Searching for value in your AI projects? ZS lights your path during Impact Live Boston 2025. bit.ly/4iSyy3z #ZSImpactLive #AIinPharma #HealthcareAI bit.ly/42hdSes

db_pavan's tweet image. Searching for value in your AI projects? ZS lights your path during Impact Live Boston 2025. bit.ly/4iSyy3z #ZSImpactLive #AIinPharma #HealthcareAI bit.ly/42hdSes

ZS has been named one of Forbes America's Best Management Consulting Firms 2025—our 10th year in a row! I am grateful to be part of a team that’s consistently raising the bar to improve life and how we live it. #lifeatZS #ForbesBest bit.ly/3RBzkWq

db_pavan's tweet image. ZS has been named one of Forbes America's Best Management Consulting Firms 2025—our 10th year in a row! I am grateful to be part of a team that’s consistently raising the bar to improve life and how we live it. #lifeatZS #ForbesBest bit.ly/3RBzkWq

Transforming R&D with integrated human health data

db_pavan's tweet image. Transforming R&D with integrated human health data

I sat down with Dr. Charles Powell, CEO, Mount Sinai Respiratory Institute and Dr. Omar Perez, Head of Medical Diagnostics at AstraZeneca, to discuss a major challenge: Lung cancer screening remains underutilized with only handful patients being screened. bit.ly/4bkAvCO

db_pavan's tweet image. I sat down with Dr. Charles Powell, CEO, Mount Sinai Respiratory Institute and Dr. Omar Perez, Head of Medical Diagnostics at AstraZeneca, to discuss a major challenge: Lung cancer screening remains underutilized with only handful patients being screened. bit.ly/4bkAvCO

The US oncology biosimilar market has grown rapidly since 2017, driven by price discounts, payer adoption and provider confidence. Stay ahead of the curve—explore the potential of upcoming biosimilars for growth and savings. Learn more. bit.ly/4g7Oc9a

db_pavan's tweet image. The US oncology biosimilar market has grown rapidly since 2017, driven by price discounts, payer adoption and provider confidence. Stay ahead of the curve—explore the potential of upcoming biosimilars for growth and savings. Learn more. bit.ly/4g7Oc9a

How does market competition lead to better patient outcomes? In this white paper, we track the impact that having more players in an indication can mean for higher diagnosis rates in rare diseases: bit.ly/4hv4hqo

db_pavan's tweet image. How does market competition lead to better patient outcomes? In this white paper, we track the impact that having more players in an indication can mean for higher diagnosis rates in rare diseases: bit.ly/4hv4hqo

Our new report includes findings across seven countries and recommendations for navigating the future of health. Download it now: bit.ly/3PAe9mJ #FutureOfHealth #ZSFOHReport bit.ly/4fYgGBW


United States Trends

Loading...

Something went wrong.


Something went wrong.